Detalhe da pesquisa
1.
mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors.
Ann Surg
; 272(5): 855-862, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32889867
2.
Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.
J Hepatol
; 65(2): 280-8, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26952006
3.
Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib.
Oncology
; 89(2): 88-94, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25871578
4.
Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B.
Hepatology
; 57(3): 953-63, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23322644
5.
CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores.
Br J Clin Pharmacol
; 77(1): 160-9, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23772874
6.
Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma.
Oncology
; 84(1): 6-13, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23075905
7.
Cytosolic and nuclear caspase-8 have opposite impact on survival after liver resection for hepatocellular carcinoma.
BMC Cancer
; 13: 532, 2013 Nov 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-24209510
8.
Liver allocation: urgency of need or prospect of success? Ethical considerations.
Clin Transplant
; 27 Suppl 25: 34-9, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23909500
9.
Effects of mycophenolate mofetil introduction in liver transplant patients: results from an observational, non-interventional, multicenter study (LOBSTER).
Clin Transplant
; 27(3): 368-78, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23405863
10.
Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation.
Langenbecks Arch Surg
; 398(8): 1123-8, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24091908
11.
The role of HBIg as hepatitis B reinfection prophylaxis following liver transplantation.
Langenbecks Arch Surg
; 397(5): 697-710, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21533917
12.
Risk factors of survival after liver transplantation for HCC: a multivariate single-center analysis.
Clin Transplant
; 25(5): E541-51, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21518002
13.
Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis.
J Neurooncol
; 97(2): 171-85, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19768634
14.
Beyond Milan criteria--chances and risks of expanding transplantation criteria for HCC patients with liver cirrhosis.
Clin Transplant
; 23 Suppl 21: 49-60, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19930317
15.
TRAIL and other TRAIL receptor agonists as novel cancer therapeutics.
Adv Exp Med Biol
; 647: 195-206, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19760076
16.
Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Clin Cancer Res
; 13(11): 3403-12, 2007 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17545549
17.
The promise of TRAIL--potential and risks of a novel anticancer therapy.
J Mol Med (Berl)
; 85(9): 923-35, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17437073
18.
Cytogenetic and molecular biological characterization of an adult medulloblastoma.
Cancer Genet Cytogenet
; 178(2): 104-13, 2007 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17954265
19.
Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs.
Clin Cancer Res
; 12(8): 2640-6, 2006 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16638878
20.
Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study.
Clin Cancer Res
; 23(19): 5720-5728, 2017 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28698202